Home » Pain Therapeutics Announces Positive Oxytrex Phase III Results
Pain Therapeutics Announces Positive Oxytrex Phase III Results
Pain Therapeutics has reported clinical results from the first of two Phase III trials with Oxytrex, a novel oral opioid painkiller.
In this Phase III study of 719 patients with severe, chronic low-back pain, Oxytrex patients reported more than 50 percent fewer symptoms of physical dependence and withdrawal effects after cessation of prolonged, high-dose opioid therapy compared to patients on oxycodone.
Oxytrex patients reported equal pain relief to patients on oxycodone and roughly 20 percent fewer overall opioid-related side effects during treatment, including less somnolence, less pruritus and 44 percent less moderate-to-severe constipation.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May